Stocktoria
Aclaris Therapeutics, Inc. ACRS
Aclaris Therapeutics, Inc. statistics & valuation
Market cap$698.3M
P / S89.2×
P / B6.8×
Net margin-829.6%
Return on equity-63.0%
FCF margin-603.4%
Return on capital-57.9%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | 52.7% | 28.3% | — |
| Operating margin | -975.9% | -758.2% | -311.6% | -302.0% | -1327.1% | -785.4% | -2627.3% | -1378.3% | -3230.0% | — |
| Net margin | -829.6% | -705.5% | -283.1% | -292.1% | -1344.0% | -787.0% | -3817.2% | -2158.0% | -4071.5% | — |
| FCF margin | -603.4% | -107.9% | -254.8% | -229.1% | -775.7% | -603.0% | -2319.8% | -1661.0% | -3321.3% | — |
| Return on assets | -40.5% | -59.9% | -44.8% | -34.1% | -36.2% | -72.1% | -164.1% | -48.2% | -28.1% | -27.3% |
| Return on equity | -63.0% | -84.9% | -56.3% | -44.0% | -46.0% | -135.5% | -230.8% | -61.7% | -30.4% | -28.4% |
| Debt / equity | — | — | — | — | — | 0.28× | — | 0.14× | — | — |
| Current ratio | 3.36 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 | 3.74 | 6.56 | 15.69 | 22.27 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.